Lipid-Based Factors: A Promising New Biomarker for Predicting Prognosis and Conditional Survival Probability in Hepatocellular Carcinoma

References

• Agosti P, Sabbà C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochim Biophys Acta Mol Basis Dis. 2018;1864(2):607–617. doi:10.1016/j.bbadis.2017.11.026
   PubMed Web of Science ®Google Scholar
• Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J. 2012;279(15):2610–2623. doi:10.1111/j.1742-4658.2012.08644.x
   PubMed Web of Science ®Google Scholar
• Zhang F, Du GW. Dysregulated lipid metabolism in cancer. World J Biol Chem. 2012;3(8):167–174. doi:10.4331/wjbc.v3.i8.167
   PubMedGoogle Scholar
• Anderson NM, Mucka P, Kern JG, et al. The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2018;9(2):216–237. doi:10.1007/s13238-017-0451-1
   PubMed Web of Science ®Google Scholar
• Li JJ, Condello S, Thomes-Pepin J, et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell. 2017;20(3):303–314. doi:10.1016/j.stem.2016.11.004
   PubMed Web of Science ®Google Scholar
• Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5(1):e189. doi:10.1038/oncsis.2015.49
   PubMed Web of Science ®Google Scholar
• Li X, Tang H, Wang J, et al. The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast. 2017;32:1–6. doi:10.1016/j.breast.2016.11.024
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang ZQ, Wang FH, et al. Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. Oncotarget. 2016;7(35):57290–57300. doi:10.18632/oncotarget.10145
   PubMedGoogle Scholar
• Jiang SS, Weng DS, Jiang L, et al. The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. J Cancer. 2016;7(6):626–632. doi:10.7150/jca.13837
   PubMed Web of Science ®Google Scholar
• Wang Q, Lau WY, Zhang B, et al. Preoperative total cholesterol predicts postoperative outcomes after partial hepatectomy in patients with chronic hepatitis B- or C-related hepatocellular carcinoma. Surgery. 2014;155(2):263–270. doi:10.1016/j.surg.2013.08.017
   PubMed Web of Science ®Google Scholar
• Zhu B, Zhang J, Zheng Q, et al. Free fatty acid is a promising biomarker in triage screening for patients with colorectal cancer: a case-control study. Cancer Manag Res. 2021;13:3749–3759. doi:10.2147/CMAR.S307753
   PubMed Web of Science ®Google Scholar
• Borgquist S, Butt T, Almgren P, et al. Apolipoproteins, lipids and risk of cancer. Int J Cancer. 2016;138(11):2648–2656. doi:10.1002/ijc.30013
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Liu C, Duan LG, Lu WS, et al. Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems. PLoS One. 2014;9(8):103228. doi:10.1371/journal.pone.0103228
   Web of Science ®Google Scholar
• Lim KC, Chow PK, Allen JC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma 19 compared to the Milan criteria. Ann Surg. 2011;254(1):108–113. doi:10.1097/SLA.0b013e31821ad884
   PubMed Web of Science ®Google Scholar
• Sasaki K, Shindoh J, Margonis GA, et al. Effect of background liver cirrhosis on outcomes of hepatectomy for hepatocellular carcinoma. JAMA Surg. 2017;152(3):e165059. doi:10.1001/jamasurg.2016.5059
   PubMed Web of Science ®Google Scholar
• Li W, Liu K, Chen Y, et al. Role of alpha-fetoprotein in hepatocellular carcinoma drug resistance. Curr Med Chem. 2021;28(6):1126–1142. doi:10.2174/0929867327999200729151247
   PubMed Web of Science ®Google Scholar
• Spolverato G, Kim Y, Ejaz A, et al. Conditional probability of long-term survival after liver resection for intrahepatic cholangiocarcinoma: a multi-institutional analysis of 535 patients. JAMA Surg. 2015;150(6):538–545. doi:10.1001/jamasurg.2015.0219
   PubMed Web of Science ®Google Scholar
• Hu LS, Zhang XF, Weiss M, et al. Redefining conditional overall and disease-free survival after curative resection for intrahepatic cholangiocarcinoma: a multi-institutional, international study of 1221 patients. J Gastrointest Surg. 2020;24(12):2756–2765. doi:10.1007/s11605-019-04472-x
   PubMed Web of Science ®Google Scholar
• Park YK, Song SK, Kim BW, et al. Conditional survival analysis demonstrates that recurrence risk of surgically treated hepatocellular carcinoma evolves with time. J Gastrointest Surg. 2017;21(8):1237–1244. doi:10.1007/s11605-017-3437-7
   PubMed Web of Science ®Google Scholar
• Shah MM, Meyer BI, Rhee K, et al. Conditional survival analysis of hepatocellular carcinoma. J Surg Oncol. 2020;122(4):684–690. doi:10.1002/jso.26049
   Web of Science ®Google Scholar
• Dong J, Zhu Y, Ma F, et al. Conditional disease-free survival after liver transplantation for hepatocellular carcinoma: a two-center experience. Medicine. 2016;95(31):e4383. doi:10.1097/MD.0000000000004383
   PubMed Web of Science ®Google Scholar
• Zhao S, Wang M, Yang Z, et al. Comparison between Child-Pugh score and Albumin-Bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC. Ann Transl Med. 2020;8(8):539. doi:10.21037/atm.2020.02.85
   PubMed Web of Science ®Google Scholar
• Liu C, Xiao GQ, Yan LN, et al. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol. 2013;19(11):1811–1819. doi:10.3748/wjg.v19.i11.1811
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):3749–3759. doi:10.1158/1078-0432.CCR-04-0713
   Web of Science ®Google Scholar
• Cucchetti A, Piscaglia F, Cescon M, et al. Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. Clin Cancer Res. 2012;18(16):4397–4405. doi:10.1158/1078-0432.CCR-11-2663
   PubMed Web of Science ®Google Scholar
• Han G, Schell MJ, Kim J. Improved survival modeling in cancer research using a reduced piecewise exponential approach. Stat Med. 2014;33(1):59–73. doi:10.1002/sim.5915
   PubMed Web of Science ®Google Scholar
• Rodrigues DSC, Fonseca I, Dias S, et al. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer. 2014;14:132. doi:10.1186/1471-2407-14-132
   PubMed Web of Science ®Google Scholar
• Nowak C, Ärnlöv J. A Mendelian randomization study of the effects of blood lipids on breast cancer risk. Nat Commun. 2018;9(1):3957. doi:10.1038/s41467-018-06467-9
   PubMed Web of Science ®Google Scholar
• Touvier M, Fassier P, His M, et al. Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies. Br J Nutr. 2015;114(3):3457–3473. doi:10.1017/S000711451500183X
   Web of Science ®Google Scholar
• Chandler PD, Song YQ, Lin J, et al. Lipid biomarkers and long-term risk of cancer in the Women’s Health Study. Am J Clin Nutr. 2016;103(6):1397–1407. doi:10.3945/ajcn.115.124321
   PubMed Web of Science ®Google Scholar
• Ni HB, Liu HX, Gao R. Serum lipids and breast cancer risk: a meta-analysis of prospective cohort studies. PLoS One. 2015;10(11):0142669. doi:10.1371/journal.pone.0142669
   Web of Science ®Google Scholar
• Martin LJ, Melnichouk O, Huszti E, et al. Serum lipids, lipoproteins, and risk of breast cancer: a nested case-control study using multiple time points. J Natl Cancer Inst. 2015;107(5):032. doi:10.1093/jnci/djv032
   Google Scholar
• Zhang Y, Yang XJ. Prognostic significance of pretreatment Apolipoprotein A-I as a noninvasive biomarker in cancer survivors: a meta-analysis. Dis Markers. 2018;2018:1034037. doi:10.1155/2018/1034037
   PubMed Web of Science ®Google Scholar
• Lonardo A, Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015;47(3):181–190. doi:10.1016/j.dld.2014.09.020
   PubMedGoogle Scholar
• Guri Y, Colombi M, Dazert E, et al. mTORC2 promotes tumorigenesis via lipid synthesis. Cancer Cell. 2017;32(6):807–823. doi:10.1016/j.ccell.2017.11.011
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2020;146(10):2439–2446. doi:10.1007/s00432-020-03331-6
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol. 2021;4:45.
   Google Scholar
• Gao H, Ji X, Liu X, et al. Conditional survival and hazards of death for peripheral T-cell lymphomas. Aging. 2021;13(7):10225–10239. doi:10.18632/aging.202782
   PubMedGoogle Scholar
• Huang F, Gao J. Modified Child-Pugh grade vs albumin-bilirubin grade for predicting prognosis of hepatocellular carcinoma patients after hepatectomy. World J Gastroenterol. 2020;26(7):749–758. doi:10.3748/wjg.v26.i7.749
   PubMed Web of Science ®Google Scholar